Brief: Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old
20/12/2024 19:16
Dec 20 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF IMCIVREE®
(SETMELANOTIDE) FOR PATIENTS AS YOUNG AS 2 YEARS OLD
Source text: ID:nGNX5BYjf0
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand